Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
- Registration Number
- NCT00378066
- Lead Sponsor
- Asan Medical Center
- Brief Summary
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
- Histologically or cytologically documented colorectal adenocarcinoma
- ECOG performance status of 2 or lower
- Adequate bone marrow function
- Adequate kidney function
- Adequate liver function
- Informed consent
Read More
Exclusion Criteria
- Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start
- Known allergy to study drugs
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bevacizumab Bevacizumab Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
- Primary Outcome Measures
Name Time Method time to progression 6 months
- Secondary Outcome Measures
Name Time Method overall survival, safety, response 1 year
Trial Locations
- Locations (6)
Yonsei University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
National Cancer Center
🇰🇷Goyang, Korea, Republic of
Bundang Seoul National University Hospital
🇰🇷Sungnam, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of